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Abstract
Background: Loss of arm function is a common and distressing consequence of stroke. We describe the protocol
for a pragmatic, multicentre randomised controlled trial to determine whether robot-assisted training improves
upper limb function following stroke.
Methods/design: Study design: a pragmatic, three-arm, multicentre randomised controlled trial, economic analysis
and process evaluation.
Setting: NHS stroke services.
Participants: adults with acute or chronic first-ever stroke (1 week to 5 years post stroke) causing moderate to
severe upper limb functional limitation.
Randomisation groups:
1. Robot-assisted training using the InMotion robotic gym system for 45 min, three times/week for 12 weeks
2. Enhanced upper limb therapy for 45 min, three times/week for 12 weeks
3. Usual NHS care in accordance with local clinical practice
Randomisation: individual participant randomisation stratified by centre, time since stroke, and severity of upper
limb impairment.
Primary outcome: upper limb function measured by the Action Research Arm Test (ARAT) at 3 months post
randomisation.
Secondary outcomes: upper limb impairment (Fugl-Meyer Test), activities of daily living (Barthel ADL Index), quality
of life (Stroke Impact Scale, EQ-5D-5L), resource use, cost per quality-adjusted life year and adverse events, at 3 and
6 months.
Blinding: outcomes are undertaken by blinded assessors.
Economic analysis: micro-costing and economic evaluation of interventions compared to usual NHS care. A within-trial
analysis, with an economic model will be used to extrapolate longer-term costs and outcomes.
Process evaluation: semi-structured interviews with participants and professionals to seek their views and experiences
of the rehabilitation that they have received or provided, and factors affecting the implementation of the trial.
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Sample size: allowing for 10% attrition, 720 participants provide 80% power to detect a 15% difference in successful
outcome between each of the treatment pairs. Successful outcome definition: baseline ARAT 0–7 must improve by 3
or more points; baseline ARAT 8–13 improve by 4 or more points; baseline ARAT 14–19 improve by 5 or more points;
baseline ARAT 20–39 improve by 6 or more points.
Discussion: The results from this trial will determine whether robot-assisted training improves upper limb function
post stroke.
Trial registration: ISRCTN, identifier: ISRCTN69371850. Registered 4 October 2013.
Keywords: Stroke, Arm, Rehabilitation, Robotics, RCT, Cost-effectiveness analysis, Parallel process evaluation
Background
Stroke is the commonest cause of complex adult disability
in high-income countries [1]. Loss of arm function affects
69% of people who have a stroke [2]. Only 12% of people
with arm weakness at the onset of stroke make a full
recovery [3]. Improving arm function has been identified
as a research priority by stroke survivors, carers and
health professionals who report that current rehabilitation
pays insufficient attention to arm recovery [4].
Robot-assisted training enables a greater number of
repetitive tasks to be practised in a consistent and
controllable manner. Repetitive task training is known to
drive Hebbian plasticity, where wiring of pathways that
are coincidently active is strengthened [5, 6]. A dose of
greater than 20 h of repetitive task training improves
upper limb motor recovery following a stroke [7] and,
therefore, robot-assisted training has the potential to im-
prove arm motor recovery after stroke. We anticipate that
Hebbian neuroplasticity, which is learning dependent, will
operate regardless of the post-stroke phase.
A Cochrane systematic review of electromechanical and
robot-assisted arm training after stroke reported outcomes
from a total of 1160 patients who participated in 34 ran-
domised controlled trials (RCTs). Improvements in arm
function (standardised mean difference (SMD) 0.35, 95%
confidence interval (CI), 0.18–0.51) and activities of daily
living (SMD 0.37, 95% CI, 0.11–0.64) were found in
patients who received this treatment, but studies were
often of low quality [8]. In the UK there is currently insuf-
ficient evidence to justify the use of this technology in
routine clinical practice.
In addition, studies which suggest that robot-assisted
training may improve upper limb function after stroke
should be treated with caution as participants who were
randomised to receive robot-assisted training may have
also received an increased intensity of rehabilitation
sessions (e.g. frequency or duration) compared to partic-
ipants in the control groups. Greater intensity of upper
limb rehabilitation sessions has been shown to improve
upper limb functional outcomes [7], and a meta-analysis of
robot-assisted training RCTs reported that if control group
therapy sessions were delivered at the same frequency and
duration, there was no additional functional improvement
[9]. Studies are required which provide further direct evi-
dence of the effectiveness of robot-assisted training without
the confounding effect of therapy dose.
The aim of the Robot Assisted Training for the Upper
Limb after Stroke (RATULS) trial is to evaluate the
clinical and cost-effectiveness of robot-assisted training
compared to an upper limb therapy programme of the
same frequency and duration, and usual post-stroke care.
The null hypothesis is that there is no difference in
upper limb function at 3 months between study partici-
pants who receive robot-assisted training and those who
receive an enhanced upper limb therapy programme and
those who receive usual post-stroke care. The RATULS
trial will be making comparisons of the effectiveness of
rehabilitation on upper limb function between all three
pairs of trial arms.
Methods
Study aim and objectives
Aim
To determine whether robot-assisted training with the
InMotion robotic gym system (InMotion commercial
version) improves upper limb function post stroke.
Objectives
 To determine whether robot-assisted training
improves upper limb function post stroke compared
to an enhanced upper limb therapy programme or
usual care
 To determine whether robot-assisted training
improves upper limb impairment, activities of daily
living and quality of life compared to an enhanced
upper limb therapy programme or usual care
 To model the costs of robotic-assisted training
compared to an enhanced upper limb therapy
programme or usual care
 To seek the views and experiences of patients and
health service professionals about the upper limb
rehabilitation that they have received or provided
and factors affecting the implementation of the trial
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 To explore:
 the time pattern of upper limb recovery of
participants in each treatment group
 the impact of the severity of baseline upper limb
function and time since stroke upon the
effectiveness of the interventions
Study design
This study is a three-arm, pragmatic, observer-blind, mul-
ticentre RCT with embedded economic analysis and a
process evaluation. Participants are randomised to receive
either: robot-assisted training (in addition to usual NHS
care); an enhanced upper limb therapy programme (in
addition to usual NHS care); or usual NHS care in accord-
ance with local clinical practice. Figure 1 summarises the
study methods. The study is presented according to
the Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) [10] (SPIRIT Checklist,
Additional file 1). Figure 2 shows the SPIRIT schedule
of enrolment, interventions and assessments.
Study setting
The study is being conducted in NHS stroke units in the
UK. There are four RATULS study centres (Glasgow,
North Tyneside, Northwick Park, and Romford) each
consisting of a hub site with an InMotion robotic gym
system and spoke sites which are stroke services in
adjacent trusts that refer patients to take part in the
study and provide usual NHS care.
Study participants
Adults with a first-ever stroke who fulfil the following
criteria are eligible to participate in the trial:
Inclusion criteria
 Age 18 years and over
 Clinical diagnosis of stroke (cerebral infarction,
primary intracerebral haemorrhage, subarachnoid
haemorrhage)
 Between 1 week and 5 years since stroke
 Moderate to severe upper limb functional limitation
(Action Research ArmTest (ARAT) [11] score 0–39)
due to stroke
 Able to provide consent to take part in the study
and to comply with the requirements of the
protocol
Exclusion criteria
 More than one stroke (patients with previous
transient ischaemic attack (TIA) may be invited to
participate)
 Other current significant impairment of the upper
limb affected by stroke, e.g. fixed contracture, frozen
shoulder, severe arthritis, recent fracture
 Diagnosis likely to interfere with rehabilitation or
outcome assessments, e.g. registered blind
 Previous use of the InMotion robotic gym system or
other arm rehabilitation robot
 Current participation in a rehabilitation trial
evaluating upper limb rehabilitation after stroke
 Previous enrolment in the RATULS study
Case ascertainment and recruitment
Study participants are recruited from both incident and
prevalent stroke populations. Participants can be sought
from a number of settings in both primary and secondary
care including: stroke units; outpatient clinics; day hospitals;
community rehabilitation services; and general practices.
The study aims to recruit similar numbers of participants
within: 0–3 months of stroke; >3–12 months after stroke;
and >12 months to 5 years after stroke.
Potential participants from secondary care
In secondary care, potential participants are identified by
local clinicians and/or staff from the National Institute
for Health Research Local Clinical Research Network
(NIHR LCRN). Staff approach potentially eligible pa-
tients, discuss the study and provide a study information
leaflet. After allowing sufficient time for the information
to be considered, staff ask the patient if they are potentially
interested in taking part in the study.
Potential participants can also be identified from
hospital stroke discharge summaries/clinic letters. If this
method is used, potential participants are approached by
letter. Enclosed with the letter is a short RATULS leaflet,
a Patient Information Sheet, a RATULS reply slip and a
pre-paid envelope. Interested patients may make contact
with the study centre by telephone or by return of the
RATULS reply slip. Following a few short telephone
questions to confirm potential study eligibility, a face-to-
face appointment for further discussion is subsequently
arranged if appropriate.
Potential participants from primary care
To identify potential participants from primary care, gen-
eral practices perform a database search using the study
inclusion/exclusion criteria. A GP screens the list of
potentially eligible participants to approve the issue of an
invitation letter. This letter is accompanied by the same
information which is sent to individuals identified from
secondary care records. The invitation letter details the
main study eligibility criteria and asks interested patients
to contact the study centre for further information.
Following a few short telephone questions to confirm
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potential study eligibility, a face-to-face appointment for
further discussion is subsequently arranged if appropriate.
Potential patients from other sources
Local community stroke clubs and day centres are also
given information about the study. In addition, some in-
dividuals may hear about the study from press releases
or see information about the study on a poster or
RATULS leaflet. Interested individuals are able to con-
tact the study centres directly for a discussion about the
study.
Consent
Individuals who are interested and potentially eligible to
take part in the study are given an appointment for
further discussion and consent. This may be conducted
by a local study coordinator or NIHR LCRN staff. Writ-
ten informed consent is obtained if the patient wishes to
take part in RATULS.
Screening log
A screening log is kept at each study centre. This re-
cords details of all inpatients, outpatients and primary
care patients considered for the study and subsequently
included or excluded.
Screening assessment
Once written informed consent is obtained, a screening
assessment is performed by the local study centre coord-
inator or NIHR LCRN staff. The following data are
Target population
720 adults at least one week post stroke with moderate to severe arm functional limitation.
Case ascertainment/recruitment
Potentially eligible patients identified from hospital services, community services and 
primary care by clinicians and NIHR LCRN staff.  
Study discussed and patient information sheet given.
Consent
Written informed consent obtained by NIHR LCRN staff or local study coordinator.
Screening/baseline assessment
Screening/baseline assessment performed by NIHR LCRN staff or local study coordinator.
Central randomisation
Newcastle University
Group 1 (n=240)
Robot assisted training
Participants receive therapy for up to 
45 minutes, 3 days per week for 12 
weeks in addition to usual NHS care
Six month assessment
Outcome measures as above plus adapted Client Services Receipt Inventory 
resource utilisation questions [20-22]
Three month assessment
1. Upper limb function (Action Research Arm Test [11])
2. Upper limb impairment (Fugl-Meyer Test [15])
3. Activities of daily living (Barthel ADL Index [16, 17])
4. Quality of life (Stroke Impact Scale [33], EQ-5D-5L [18])
5. Adverse events including upper limb pain
Group 2 (n=240)
Enhanced upper limb therapy 
programme
Participants receive therapy for up to 
45 minutes, 3 days per week for 12 
weeks in addition to usual NHS care
Group 3 (n=240)
Usual care
Participants receive usual NHS care 
in accordance with local clinical 
practice
Process 
evaluation
interviews 
patients
Process 
evaluation
interviews 
health 
professionals
Fig. 1 RATULS trial summary
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collected: demography; stroke details; comorbidity; and
upper limb function (ARAT score [11]). If the patient
fulfils the study inclusion and exclusion criteria, the local
study coordinator/NIHR LCRN staff proceeds to the
baseline assessment. If it is not possible to complete the
baseline assessment on the same day as the screening
Study period
Enrolment Allocation Post-allocation
Screening Baseline 3 months 6 months
Assessment/ activity -t1 0 t1 t2
Screening 
assessment
Written informed consent x
Contact details x
Demography x
Stroke details x
Comorbidity x
Upper limb function (Action 
Research Arm Test [11]) x
Baseline 
assessment
Stroke severity (National Institute for 
Health Stroke Scale [12])
x
Cognition function (Montreal 
Cognitive Assessment [13]) x
Language skills (Sheffield Aphasia 
Screening Test [14]) x
Upper limb impairment (Fugl-Meyer 
motor and sensory arm sections 
[15])
x
Activities of daily living (Barthel ADL 
Index [16, 17]) x
Quality of life (EQ-5D-5L [18]) x
Upper limb pain (numerical rating 
scale [19]) x
Current upper limb rehabilitation 
treatments
x
Randomisation x
Pre-study resource utilisation
(adaptation of the Client Services 
Receipt Inventory [20-22])
x
Issue of study arm rehabilitation logs x
Interventions
Robot-assisted training in addition to 
usual care
Enhanced upper limb therapy in 
addition to usual care
Usual care
Outcome 
assessments
Upper limb function (Action 
Research Arm Test [11])
x x
Upper limb impairment (Fugl-Meyer 
motor and sensory arm sections 
[15])
x x
Activities of daily living (Barthel ADL 
Index [16, 17]) x x
Quality of life (EQ-5D-5L [18]) x x
Impact of stroke
(Stroke Impact Scale [33]) x x
Upper limb pain (numerical rating 
scale [19])
x x
Adverse Events x x
Resource utilisation (adaptation of 
the Client Services Receipt Inventory 
[20-22])
x
Time and travel resource utilisation 
[34, 35]
x
Issue of study arm rehabilitation logs x
Fig. 2 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) schedule of enrolment, interventions and assessments
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assessment, eligibility for the study is re-confirmed on
the day of the baseline assessment.
Baseline assessment
The following baseline data are collected: stroke severity
(National Institute for Health Stroke Scale [12]); cogni-
tive function (Montreal Cognitive Assessment [13]);
language skills (Sheffield Aphasia Screening Test [14]);
upper limb impairment (Fugl-Meyer Test (motor and
sensory arm sections) [15]); activities of daily living
(Barthel ADL Index [16, 17]; quality of life (EQ-5D-5 L
[18]); upper limb pain (numerical rating scale [19]) and
current upper limb rehabilitation treatments. In addition,
patients are given a self-completion questionnaire con-
taining pre-study resource utilisation questions (adaption
of the Client Services Receipt Inventory [20–22]) which
they are asked to complete at the end of the assessment.
Randomisation
Randomisation is conducted by the local study coordin-
ator/NIHR LCRN staff following completion of the base-
line assessment. A central independent web-based service
hosted by Newcastle University Clinical Trials Unit is
used. Participants are stratified according to study centre,
time since stroke and severity of upper limb function
(ARAT score [11]), and randomised to either robot-
assisted training, enhanced upper limb therapy, or usual
care groups using permuted block sequences.
Randomisation groups
Robot-assisted training using the InMotion robotic gym
system
This is delivered using the InMotion robotic gym system
which was specifically designed for clinical rehabilitation
applications [23–25]. This is currently the most widely
used technology for robot-assisted training for patients
with moderate to severe upper limb impairment post
stroke. The system development started in 1989 and it
has amassed the largest body of clinical evidence to date
of any robotic system. It has been successfully tested in
clinical studies involving over 900 stroke patients and
there are around 250 robots in use worldwide.
Participants receive robot-assisted training at the hub
sites for up to 45 min per day, three days per week for
12 weeks, in addition to usual care. A detailed descrip-
tion of the robot-assisted training programme using the
Template for Intervention Description and Replication
(TIDieR) Checklist [26] is provided in Table 1.
Enhanced upper limb therapy programme
The enhanced upper limb therapy programme aims to
match the frequency and duration of the robot-assisted
training programme sessions. It has been developed
from the upper limb therapy programmes used in the
Botulinum Toxin for the Upper Limb after Stroke
(BoTULS) trial [27–29] and the Repetitive Arm Func-
tional Tasks after Stroke (RAFTAS) project [30]. Using
the principles of person-centred goal-setting and repetitive
functional task practice, it aims to drive neuroplasticity
and motor recovery after stroke.
Participants receive enhanced upper limb therapy at the
hub sites for up to 45 min per day, 3 days per week for
12 weeks, in addition to usual care. A detailed description
of the enhanced upper limb therapy programme using the
TIDieR Checklist [26] is provided in Table 1.
Usual care
Defining usual care is a challenge for any stroke rehabili-
tation trial. One of the current NICE quality standards is
that ‘patients with stroke should be offered a minimum
of 45 min of each appropriate therapy that is required,
for a minimum of 5 days a week, at a level that enables
the patient to meet their rehabilitation goals for as long
as they are continuing to benefit from therapy and as
long as they are able to tolerate it’ [31]. For most stroke
services this is aspirational and the majority of patients
do not receive this intensity particularly after discharge
from hospital or early supported discharge services [32].
Patients with chronic stroke are unlikely to receive on-
going rehabilitation in the longer term. Most services do
not regularly review patients to address unmet rehabili-
tation needs beyond 1 year.
Usual care is delivered at hub and spoke sites.
Participants in all three randomisation groups receive
a study ‘arm rehabilitation therapy log’ where they are
asked to record any ‘usual’ upper limb rehabilitation that
they receive during the course of the study. Periodic text
message reminders are sent to remind participants about
completion of the rehabilitation logs. In addition, partici-
pants in all three randomisation groups receive regular
study newsletters.
Outcome assessments
Outcomes are assessed at 3 months (±7 days) and
6 months (±7 days) following randomisation.
Assessments are undertaken in two stages:
Stage 1 is a self-completion postal questionnaire consist-
ing of the Stroke Impact Scale (SIS) [33] (3 and 6 months)
and the adapted Client Services Receipt Inventory resource
utilisation questions (6 months only) [20–22].
Stage 2 is a face-to-face assessment with a researcher
blinded to randomisation group. The following data are
collected: Barthel ADL Index [16, 17], EQ-5D-5L [18],
ARAT [11], Fugl-Meyer Test (motor and sensory arm sec-
tions [15]), and adverse events. At the end of the 6-month
stage-2 assessment, participants are given a further self-
completion questionnaire and are asked to return this by
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post. This questionnaire contains time and travel resource
use questions [34, 35].
Blinding
Due to the nature of the interventions, it is not possible
to blind participants or treating therapists to treatment
allocation. It is intended that stage-2 outcome assess-
ments are conducted by a researcher blinded to treat-
ment allocation. After each outcome assessment the
researcher is asked to record whether they have uninten-
tionally become aware of treatment allocation due to
conversation with the participant. Success of outcome
assessment blinding will be reported.
Study withdrawal
No specific withdrawal criteria have been pre-set. Partic-
ipants may withdraw from the study at any time for any
reason. Data collected prior to withdrawal will be used
in the study analysis unless consent for this is specifically
withdrawn. Should a decision to withdraw from the
study be made, a reason for withdrawal is sought but
participants can chose to withdraw without providing an
explanation.
Investigators, GPs, stroke physicians and therapists
may also withdraw participants from the study at any
time if they feel it is no longer in their interest to
continue; for example, because of intercurrent illness or
adverse events.
Safety evaluation
The safety of robot-assisted training, enhanced upper
limb therapy and usual care is being evaluated by exam-
ining the occurrence of all adverse events and serious
adverse events in accordance with National Research
Ethics Committee (NRES) guidance for non-CTIMP
trials [36].
Statistical analysis
Primary analysis
The primary outcome is arm function measured by the
ARAT [11] at 3 months. It has been suggested that the
minimal clinically important difference for the ARAT is
10% of its range (6 points) [37] but a smaller treatment
effect may be clinically beneficial in those with severe
initial upper limb functional limitation who are likely to
improve less than those with more moderate limitation.
There will be a stepped approach to define ‘successful
outcome’: baseline ARAT 0–7 must improve by 3 or
more points; baseline ARAT 8–13 improve by 4 or more
points; baseline ARAT 14–19 improve by 5 or more
points; baseline ARAT 20–39 improve by 6 or more
points. Analyses will be by intention-to-treat. Logistic re-
gression will be used to compare the primary outcome
(success) between the three randomisation groups at 3
and 6 months, adjusting for any imbalance in key covari-
ates. The use of multilevel logistic models will be ex-
plored. It may be possible to fit three-level models
(hubs, spokes and participants), but since there are only
four centres with a hub, and a small number of stroke
services accessing an InMotion robotic gym system at
each hub, it may be necessary to fit a two-level model
(stroke services and participants).
Secondary analyses
The secondary outcomes will be compared between the
three groups at 3 and 6 months using multilevel linear re-
gression adjusting for baseline values and key covariates.
We will consider any difference in attrition rates, and
any nonrandomness of the attrition, when comparing
outcomes between the three groups. The pattern of
missing observations because of loss to follow-up will be
examined to determine both the extent of missingness,
and whether it is missing at random or is informative. If
data are missing to a sufficient extent, the use of appro-
priate multiple imputation techniques will be consid-
ered. Although mortality is possible within the 6-month
follow-up period, it is thought to be sufficiently uncom-
mon that methods for joint modelling of survival and
longitudinal data will not be necessary.
Further descriptive analyses will explore the relation-
ship between the severity of baseline upper limb func-
tion and time since stroke upon the effectiveness of the
intervention. There is not sufficient power to perform
any formal subgroup analyses. The time pattern of upper
limb recovery will be explored by extending the earlier
multilevel models to include a further within-patient
level (ARAT scores collected at baseline, 3 and
6 months). However, this will depend on the relationship
being approximately linear.
Sample size
The sample size is 720 participants (240 participants per
group). Responses from 216 participants in each ran-
domisation group will provide 80% power (significance
level of 1.67% because of multiple comparisons) to de-
tect a 15% difference in ‘successful outcome’ between
each of the three pairs of treatments (robot-assisted
training, enhanced upper limb therapy, usual care). We
have allowed for 10% attrition and inflated the sample
size to 720 participants.
Economic analysis
The economic analysis will include a detailed micro-
costing analysis, economic evaluation and a longer-term
economic model. This will be based upon both a ‘within
trial’ analysis and a modelling exercise to explore costs
and effects over the longer term. Analyses will be carried
out from the perspective of the NHS and personal and
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social services, but we will also take a societal perspec-
tive by including costs borne by the participants and
their informal carers. All relevant costs associated with
providing the interventions will be measured, this will
include the cost of using the InMotion robotic gym
system, costed on a per patient basis. All costs will be
derived using routine data sources [38] and study-
specific estimates. Where appropriate, discounting will
be applied to costs and outcomes [39]. Costs in the
follow-up period will also be taken into account; this in-
cludes secondary care resource, e.g. inpatient stays and
outpatient visits; primary care resource use, e.g. general
practice, therapy visits and prescription costs. These data
will be collected using a health service utilisation ques-
tionnaire (adaption of the Client Services Receipt Inven-
tory [20–22]) administered at baseline and 6 months
post randomisation. Patient costs will also be collected
via a time-and-travel questionnaire based upon one
successfully used in a number of previous NIHR HTA-
funded trials [34, 35]. This will include questions relating
to travel time, time away from employment (if appropri-
ate) and time spent providing care. The within-trial ana-
lysis will also compare changes in health-related quality
of life, based on responses to the EQ-5D-5L at baseline,
3 and 6 months post randomisation and scored using
population tariffs [40]. These data will be combined with
study participants’ mortality to estimate quality-adjusted
life years (QALYs). This measure provides a profile of
quality of life over time. The results of the analyses will
be presented as point estimates of mean incremental
costs and QALYs. Techniques, such as bootstrapping,
will be used alongside deterministic sensitivity analyses
to address uncertainty [41]. In addition, a within trial cost-
utility analysis will be performed where both costs and
QALY data will be combined into an incremental cost per
QALY. The cost-utility analysis will include deterministic
and stochastic sensitivity analysis, presented as point esti-
mates and cost-effectiveness acceptability curves (CEACs).
An economic model will also be developed to assess the
cost and health consequences measured in terms of
QALYs of stroke recovery beyond the 6-month timeframe
of the trial. The data from the trial will be the main source
of data for this model but further data with which to
model outcomes beyond a 6-month follow-up will be sys-
tematically derived from the academic literature and other
existing data sources following guidance for best practice
[42]. These data will include information on factors, such
as the incidence of hospitalisation and the need for resi-
dential/nursing home care, beyond the trial follow-up
period. Sensitivity analysis will be applied to the model
using probabilistic and deterministic sensitivity analyses to
address parameter and other forms of uncertainty. The
data on both costs and QALYs for both trial- and model-
based analyses will be reported separately.
Parallel process evaluation
Alongside the RCT, a two-stage process evaluation is be-
ing conducted to understand both (1) participants‘ and
health service professionals’ experiences of robot-assisted
training; enhanced upper limb therapy and usual care and
(2) factors affecting the implementation of the trial within
and across study sites. The process evaluation will capture
data concerning feasibility and accumulating experience
of the therapies being provided. In stage 1 data collection
is by semi-structured interview using a pre-developed and
piloted interview schedule. Data collection in stage 2 is
primarily by interview; however, analysis also draws upon
trial data including baseline, therapy and outcome (3 and
6 month) assessments. Interviews are primarily being con-
ducted face to face; however, due to the geographical
spread of the study sites, some follow-up interviews are
being conducted by telephone for efficiency (these are
particularly appropriate for health service professionals).
Data collection and analysis relating to study of imple-
mentation factors will be informed by Normalization
Process Theory (NPT) [43].
Participant study group
In stage 1 a subset of approximately 25–30 study partici-
pants will be recruited across study sites, to achieve a
maximum variation sample, ensuring representation of
participants differing in terms of key factors such as ran-
domisation group, clinical severity and time from stroke.
Participants in the robot-assisted training and enhanced
upper limb therapy programme groups are interviewed
on two occasions: (1) soon after therapy commences and
(2) towards the end of the 12-week therapy period, to
determine how perceptions of acceptability of therapy
may change over time.
In stage 2 approximately 25 participants will be re-
cruited, again with the aim of achieving maximum vari-
ation in the sample. Participants in the treatment groups
are interviewed twice. However, in this stage, time points
are (1) towards the end of their 12-week therapy and (2)
around their 6-month follow-up assessments, to provide
insight into their experience of trial participation, and
the impact of the therapy they received, post treatment.
The baseline, therapy and outcome assessment data are
reviewed descriptively, for the participants who have
been interviewed as part of stage 2. This will allow
comparison of trial participants’ assessment data with
their subjective experiences of participating in the trial,
to inform later interpretation of the results of the trial.
Participants to be invited for interview are identified
from the study database (containing data held by unique
study number only) by the researcher conducting the in-
terviews. The researcher advises the local study centre
coordinators/administrators of the selected participant
numbers and the local study coordinator/administrator/
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LCRN staff mails an invitation letter, an Information
Sheet and a self-completion Contact Details Form for
the participant to return directly to the researcher if they
are interested in taking part in the interview(s).
The researcher telephones the responding participants,
describes the purpose of the interview(s) and agrees a
mutually convenient time for a first interview to take
place. Prior to any potential second interview, partici-
pants are re-contacted by the researcher to check that
they are still willing to take part in the second interview.
Consent to be interviewed is obtained in writing prior to
commencement of each interview.
Health service professional study group
A sample of approximately 20 health service profes-
sionals is being recruited across study sites and study
groups. Interviews take place in stage 1 and stage 2 of
the process evaluation. The aim is to interview a range
of health service professionals, e.g. senior therapists,
therapy assistants, study administrators, principal inves-
tigators and NIHR LCRN staff to gain insight into differ-
ent aspects of the trial including implementation of the
robot-assisted training, enhanced upper limb therapy
and usual care practices, and implementation of the trial
itself, including the recruitment and follow-up processes.
Staff to be invited for interview are identified by the
local study centre coordinator and/or local study investi-
gators. Each selected member of staff receives a letter of
invitation and an Information Sheet. Following issue of
the invitation letter and Information Sheet, the re-
searcher conducting the interviews contacts the selected
staff to go over the purpose of the interviews and ascer-
tain willingness to take part. A mutually convenient time
and place for the interview(s) is agreed. Consent to be
interviewed is obtained in writing prior to commence-
ment of each interview.
Interview data analysis
Interviews are audio-taped with the respondents’ con-
sent, and transcribed. Data will be mostly analysed
using the constant comparative method of qualitative
analysis [44] facilitated by analysis software (QSR
NVivo). For a subset of the process evaluation data –
that specifically focussed on questions concerning im-
plementation – a theory-based approach to analysis will
be undertaken [43]. All data analysis will include a pro-
portion of data to be analysed collectively in ‘data
clinics’ where the research team share and exchange
interpretations of key themes emerging from the data.
A larger proportion of data, however, will be independ-
ently thematically coded and compared between two
researchers to ensure consistency in the interpretation
of data within a broader thematic framework developed
as data collection progresses.
Confidentiality
Personal data are regarded as strictly confidential. Original
paper Case Record Forms containing study data are stored
in the investigator site file at each research site. All study
files are securely stored and access restricted to staff in-
volved in the study. Research staff at sites enter data from
paper forms onto a secure web-based electronic database
run and maintained by Newcastle University. Data are
entered using participant-unique study numbers only.
Access to this database is password-protected and limited
to staff at research sites or Newcastle University who are
involved in the study.
The InMotion robotic gym computers store data from
each participant session. Data are stored by unique study
number only. Periodically, these data are copied from
the robot computer system into an electronic database
maintained by Newcastle University.
The study complies with the Data Protection Act
1998, and Caldicott Guardian approval for use of patient
identifiable data.
Trial monitoring, quality control and quality assurance
The chief investigator has overall responsibility for study
conduct. The principal investigators are responsible for
the day-to-day study conduct at their individual sites.
The trial is managed by a coordinating centre based at
Newcastle University which provides day-to-day support
for the sites and provides training through investigator
meetings, site initiation visits and routine monitoring
visits. A Trial Management Group (TMG) has been con-
vened and the TMG meets regularly during the study.
Quality control is maintained through adherence to
Newcastle Biomedicine Clinical Research Platform SOPs,
the study protocol and research governance regulations.
General monitoring of study conduct and data collected is
being performed by a combination of central review and
site-monitoring visits. The main areas of focus include
consent, serious adverse events and essential documents
in study files. All monitoring findings are reported and
followed up with the appropriate persons in a timely
manner.
A Trial Steering Committee (TSC) has been convened.
This comprises an independent chair, three other inde-
pendent members, a patient and/or a carer representative
and the chief investigator. The TSC has agreed a charter
of operation and meet at least annually.
An independent Data Monitoring and Ethics Commit-
tee (DMEC) has been convened to undertake independ-
ent review. This comprises five independent members
including expert health care professionals and a statisti-
cian. Only the DMEC has access to unblinded outcome
data before the trial ends. The DMEC has agreed a
charter of operation and meets at least annually.
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Dissemination of results
The data are the property of the chief investigator and
co-investigator(s). Publication will be the responsibility
of the chief investigator.
The study will be presented at national and international
conferences, and reported in peer-reviewed journals and a
NIHR HTA monograph. Reports will be written for the
study sponsor and regulatory bodies. A summary of the
results will be sent to study participants and be available
on the study website: https://research.ncl.ac.uk/ratuls/.
Anonymised data will be provided to research databases
as requested (e.g. the Cochrane Collaboration, the Virtual
International Stroke Trials Archive (VISTA)) to enable
future meta-analyses. Anonymised robot kinematic and
kinetic data will be provided to co-investigators for explora-
tory analyses.
Discussion
Robot-assisted training is a promising treatment for im-
proving the upper limb function of patients with moder-
ate to severe upper limb impairment post stroke, but
further high-quality research is needed before this tech-
nology should be integrated into clinical practice [8].
RATULS is a large, multicentre RCT to determine
whether robot-assisted training with the InMotion robotic
gym system (MIT-Manus commercial version) improves
upper limb function post stroke when compared to an
upper limb therapy programme of the same frequency
and duration of sessions and usual NHS care. The results
from the trial will inform clinicians and commissioners of
health care about the clinical effectiveness and cost-
effectiveness of robot-assisted training.
Trial status
RATULS commenced recruitment in April 2014. Four
NHS study centres (Glasgow, North Tyneside, Northwick
Park, and Romford) are participating. The RATULS trial
has recruited 468 patients at the time of submission of this
manuscript. Protocol version 3, dated 2 August 2016, was
used to prepare the manuscript.
Additional file
Additional file 1: SPIRIT Checklist for RATULS protocol paper.
(DOC 120 kb)
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